Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TSN1611 in Advanced Solid Tumors Harboring KRAS G12D Mutation
NCT06385925Phase 2Recruiting
- Sponsor
- Tyligand Bioscience
- Start
- Apr 2024
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of TSN1611 in solid tumor, pancreatic cancer (PC), colorectal cancer (CRC) and 1 more (5 arms), sponsored by Tyligand Bioscience. Primary endpoints: Dose limiting toxicities at 21 days and Objective response rate up to 3 years. Started Apr 2024; status: recruiting.
02
Drugs
TSN1611
03
Conditions
solid tumorpancreatic cancer (PC)colorectal cancer (CRC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06385925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06385925.